

Publications et communications - 2023-2024

Publications nationales

Autran B, Lefrancois T, **Lina B**; les membres du Comité de Veille et d'Anticipation des Risques Sanitaires (COVARs). [The mission of COVARs: how to anticipate health risks within a "One Health" vision of the exposome]. Med Sci (Paris). 2024 Jun-Jul;40(6-7):485-486.

Lina B, Influenzavirus, (2024) traité EMC Traité de Médecine Akos, Elsevier Masson SAS B. [Article 4-1200].

Epelboin L, Abboud P, Abdelmoumen K, About F, Adenis A, Blaise T, Blaizot R, Bonifay T, Bourne-Watrin M, Boutrou M, Carles G, Carlier PY, Carod JF, Carvalho L, Couppe P, De Toffol B, Delon F, Demar M, Destoop J, Douine M, Droz JP, Elenga N, **Enfissi A**, Franck YK, Fremery A, Gaillet M, Kallel H, Kpangon AA, **Lavergne A**, Le Turnier P, Maisonnobe L, Michaud C, Mutricy R, Nacher M, Naldjinan-Kodbaye R, Oberlis M, Odonne G, Osei L, Pujo J, Rabier S, Roman-Laverdure B, Rousseau C, **Rousset D**, Sabbah N, Sainte-Rose V, Schaub R, Sylla K, Tareau MA, Tertre V, Thorey C, Vialette V, Walter G, Zappa M, Djossou F, Vignier N. Panorama des pathologies infectieuses et non infectieuses de Guyane en 2022. MTSI-Revue 2023 Vol 3, N°1. <https://doi.org/10.48327/mtsi.v3i1.2023.308>

Bernard-Stoecklin S, **Equipes de surveillance de la grippe***. Surveillance de la grippe en France, saison 2022-2023. 2023. BEH 19 :381-397.

Publications internationales

Publication communes CNR

2024

Brault A, Pontais I, **Enouf V**, Debeuret C, Bloch E, Paireau J, **Rameix-Welti MA**, White M, Baudemont G, **Lina B**, Parent du Châtelet I, **Casalegno JS**, Vaux S, Cauchemez S. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study. Lancet Child Adolesc Health. 2024 Aug 26:S2352-4642(24)00143-3. doi: 10.1016/S2352-4642(24)00143-3. Epub ahead of print. PMID: 39208833.

Planas D, Staropoli I, Michel V, Lemoine F, **Donati F**, Prot M, Porrot F, Guivel-Benhassine F, Jeyarajah B, Brisebarre A, **Dehan O**, Avon L, Bolland WH, Hubert M, Buchrieser J, Vanhoucke T, Rosenbaum P, Veyer D, Péré H, **Lina B**, Trouillet-Assant S, Hocqueloux L, Prazuck T, **Simon-Loriere E**, Schwartz O. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat Commun. 2024 Mar 13;15(1):2254.

Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, Hooiveld M, Gomez V, Domegan L, Martínez-Baz I, Ilić M, Carnahan AS, Mihai ME, Martínez A, Goerlitz L, **Enouf V**, Horváth JK, Dijkstra F, Rodrigues AP, Bennett C, Trobajo-Sanmartín C, Mlinarić I, Latorre-Margalef N, Ivanciuc A, Lopez A, Dürrwald R, Falchi A, Túri G, Meijer A, Melo A, O'Donnell J, Castilla J, Vučina VV, Hagey TS, Lazar M, Kaczmarek M, Bacci S, Kissling E; **VEBIS study team** Influenza vaccine

effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study - 2024 Jan 10;18(1):e13243. doi: 10.1111/irv.13243.

Participation à publication – Liste de publiants (CNR-HCL et CNR-IPP)

Marchal A, Cirulli ET, Neveux I, Bellos E, Thwaites RS, Schiabor Barrett KM, Zhang Y, Nemes-Bokun I, Kalinova M, Catchpole A, Tangye SG, Spaan AN, Lack JB, Ghosn J, Burdet C, Gorochoy G, Tubach F, Hausfater P; COVID Human Genetic Effort; COVDeF Study Group; **French COVID Cohort Study Group**; **CoV-Contact Cohort**; COVID-STORM Clinicians; COVID Clinicians; Orchestra Working Group; Amsterdam UMC COVID-19 Biobank; NIAID-USUHS COVID Study Group; Dalgard CL, Zhang SY, Zhang Q, Chiu C, Fellay J, Grzymalski JJ, Sancho-Shimizu V, Abel L, Casanova JL, Cobat A, Bolze A. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection. HGG Adv. 2024 Jul 18;5(3):100300. doi: 10.1016/j.xhgg.2024.100300. Epub 2024 Apr 26. PMID: 38678364; PMCID: PMC11215417.

Citarella BW, Kartsonaki C, Ibáñez-Prada ED, Gonçalves BP, Baruch J, Escher M, Pritchard MG, Wei J, Philipp F, Dagens A, Hall M, Lee J, Kutsogiannis DJ, Wils EJ, Fernandes MA, Tirupakuzhi Vijayaraghavan BK, Panda PK, Martin-Loeches I, Ohshimo S, Fatoni AZ, Horby P, Dunning J, Rello J, Merson L, Rojek A, Vaillant M, Olliaro P, Reyes LF; **ISARIC Clinical Characterisation Group**. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms. Heliyon. 2024 May 4;10(10):e29591

Mesinovic M, Wong XC, Rajahram GS, Citarella BW, Peariasamy KM, van Someren Greve F, Olliaro P, Merson L, Clifton L, Kartsonaki C; **ISARIC Characterisation Group**. At-admission prediction of mortality and pulmonary embolism in an international cohort of hospitalised patients with COVID-19 using statistical and machine learning methods. Sci Rep. 2024 Jul 16;14(1):16387.

Presser LD, van den Akker WMR, Meijer A; **PROMISE Investigators**. Respiratory Syncytial Virus European Laboratory Network 2022 Survey: Need for Harmonization and Enhanced Molecular Surveillance. J Infect Dis. 2024 Mar 1;229(Supplement_1):S34-S39. doi: 10.1093/infdis/jiad341.

Cong B, Koç U, Bandeira T, Bassat Q, Bont L, Chakhunashvili G, Cohen C, Desnoyers C, Hammit LL, Heikkinen T, Huang QS, Markić J, Mira-Iglesias A, Moyes J, Nokes DJ, Ploin D; **VRS study group in Lyon**; Seo E, Singleton R, Wolter N, Fu Yung C, Zar HJ, Feikin DR, Sparrow EG; **Respiratory Virus Global Epidemiology Network**; Nair H, Li Y; **PROMISE investigators**. Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis. Lancet Infect Dis. 2024 Apr;24(4):361-374.

Siempos II, Kalil AC, Belhadi D, Veiga VC, Cavalcanti AB, Branch-Elliman W, Papoutsis E, Gkirkiris K, Xixi NA, Kotanidou A, Hermine O, Porcher R, Mariette X; CORIMUNO-19 Collaborative Group; **DisCoVeRy Study Group**; ACTT-2 Study Group; ACTT-3 Study Group. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials. EClinicalMedicine. 2024 Feb 9;69:102472.

Cho SM, Premraj L, Battaglini D, Fanning JP, Suen J, Bassi GL, Fraser J, Robba C, Griffie M, Solomon T, Semple MG, Baillie K, Sigfrid L, Scott JT, Citarella BW, Merson L, Arora RC, Whitman G, Thomson D, White N; **ISARIC Clinical Characterization Group**. Sex differences in post-acute neurological sequelae of SARS-CoV-2 and symptom resolution in adults after coronavirus disease 2019 hospitalization: an international multi-centre prospective observational study. Brain Commun. 2024 Feb 9;6(2):fcae036.

Battaglini D, White NM, Premraj L, Wanjiro Citarella B, Merson L, Robba C, Thomson D, Cho SM; ISARIC Clinical Characterization Group. Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the **ISARIC-COVID-19 follow-up study**. J Neurol. 2024 Jan;271(1):79-86. doi: 10.1007/s00415-023-12133-y. Epub 2023 Dec 6. PMID: 38055020; PMCID: PMC10769963.

Parraud D., Maucotel A.L., **Bouscambert M.**, Morfin F., Bitker L., Chidiac C., De Castro N., Frobert E., **Gaymard A.**, and the French COVID cohort study group. SARS-CoV-2 N-antigen quantification in respiratory tract, plasma and urine: kinetics and association with RT-qPCR results. *Viruses*, 2023

Néant N., Lingas G., **Gaymard A.**, Belhadi D., Hites M., Staub T., Greil R., Paiva J.-A., Poissy J., Peiffer-Smadja N., Costagliola D., Yazdanpanah Y., **Bouscambert-Duchamp M.**, Gagneux-Brunon A., Ader F., Mentré F., Wallet F., Burdet C., Guedj J., & **DisCoVeRy study group**. Association between SARS-CoV-2 viral kinetics and clinical score evolution in hospitalized patients. *CPT: pharmacometrics & systems pharmacology*, 2023.

Briand FX, Souchaud F, Pierre I, Beven V, Hirschaud E, Hérault F, Planel R, Rigaudeau A, Bernard-Stoecklin S, **Van der Werf S**, Lina B, Gerbier G, Eterradossi N, Schmitz A, Niqueux E, Grasland B. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022. *Emerg Infect Dis*. 2023 Aug;29(8):1696-1698.

Participation à publication – Liste de publiants (CNR-HCL et CNR-IPP)

Matuozzo D, Talouarn E, Marchal A, Zhang P, Manry J, Seeleuthner Y, Zhang Y, Bolze A, Chaldebas M, Milisavljevic B, Gervais A, Bastard P, Asano T, Bizien L, Barzaghi F, Abolhassani H, Abou Tayoun A, Aiuti A, Alavi Darazam I, Allende LM, Alonso-Arias R, Arias AA, Aytekin G, Bergman P, Bondesan S, Bryceson YT, Bustos IG, Cabrera-Marante O, Carcel S, Carrera P, Casari G, Chaïbi K, Colobran R, Condino-Neto A, Covill LE, Delmonte OM, El Zein L, Flores C, Gregersen PK, Gut M, Haerynck F, Halwani R, Hancerli S, Hammarström L, Hatipoğlu N, Karbuz A, Keles S, Kyheng C, Leon-Lopez R, Franco JL, Mansouri D, Martinez-Picado J, Metin Akcan O, Migeotte I, Morange PE, Morelle G, Martin-Nalda A, Novelli G, Novelli A, Ozcelik T, Palabiyik F, Pan-Hammarström Q, de Diego RP, Planas-Serra L, Pleguezuelo DE, Prando C, Pujol A, Reyes LF, Rivière JG, Rodriguez-Gallego C, Rojas J, Rovere-Querini P, Schlüter A, Shahrooei M, Sobh A, Soler-Palacin P, Tandjaoui-Lambiotte Y, Tipu I, Tresoldi C, Troya J, van de Beek D, Zatz M, Zawadzki P, Al-Muhsen SZ, Alosaimi MF, Alshome FM, Baris-Feldman H, Butte MJ, Constantinescu SN, Cooper MA, Dalgard CL, Fellay J, Heath JR, Lau YL, Lifton RP, Maniatis T, Mogensen TH, von Bernuth H, Lermine A, Vidaud M, Boland A, Deleuze JF, Nussbaum R, Kahn-Kirby A, Mentre F, Tubiana S, Gorochoff G, Tubach F, Hausfater P; COVID Human Genetic Effort; COVIDeF Study Group; **French COVID Cohort Study Group**; **CoV-Contact Cohort**; COVID-STORM Clinicians; COVID Clinicians; Orchestra Working Group; Amsterdam UMC Covid-19 Biobank; NIAID-USUHS COVID Study Group; Meyts I, Zhang SY, Puel A, Notarangelo LD, Boisson-Dupuis S, Su HC, Boisson B, Jouanguy E, Casanova JL, Zhang Q, Abel L, Cobat A. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. *Genome Med*. 2023 Apr 5;15(1):22. doi: 10.1186/s13073-023-01173-8. Erratum in: *Genome Med*. 2024 Jan 6;16(1):6. doi: 10.1186/s13073-023-01278-0. PMID: 37020259; PMCID: PMC10074346.

Reyes LF, Garcia-Gallo E, Murthy S, Fuentes YV, Serrano CC, Ibáñez-Prada ED, Lee J, Rojek A, Citarella BW, Gonçalves BP, Dunning J, Rätsep I, Viñan-Garces AE, Kartsonaki C, Rello J, Martin-Loeches I, Shankar-Hari M, Olliaro PL, Merson L; **ISARIC Characterisation Group**. Major adverse cardiovascular events (MACE) in patients with severe COVID-19 registered in the ISARIC WHO clinical characterization protocol: A prospective, multinational, observational study. *J Crit Care*. 2023 Oct;77:154318. doi: 10.1016/j.jcrc.2023.154318. Epub 2023 May 9. PMID: 37167775; PMCID: PMC10167415.

Tirupakuzhi Vijayaraghavan BK, Bishnu S, Baruch J, Citarella BW, Kartsonaki C, Meeyai A, Mohamed Z, Ohshimo S, Lefèvre B, Al-Fares A, Calvache JA, Taccone FS, Olliaro P, Merson L, Adhikari NKJ; **ISARIC Clinical Characterisation Group**. Liver injury in hospitalized patients with COVID-19: An International observational cohort study. *PLoS One*. 2023 Sep 13;18(9):e0277859. doi: 10.1371/journal.pone.0277859. PMID: 37703268; PMCID: PMC10499210.

Griffie MJ, Bozza PT, Reyes LF, Eddington DP, Rosenberger D, Merson L, Citarella BW, Fanning JP, Alexander PMA, Fraser J, Dalton H, Cho SM; **ISARIC Clinical Characterisation Group**. Thrombotic and hemorrhagic complications of

COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry. *Res Pract Thromb Haemost*. 2023 Jul 1;7(5):102142.

Wainstein M, Spyrisson N, Dai D, Ghadimi M, Chávez-Iñiguez JS, Rizo-Topete L, Citarella BW, Merson L, Pole JD, Claude-Del Granado R, Johnson DW, Shrapnel S; **ISARIC Characterization Group**. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19. *Kidney Int Rep*. 2023 May 27;8(8):1514-30.

Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, Trebbien R, Watson C, Findlay B, Pozo F, Bolt Botnen A, Harvey C, Rose A; **European IVE group; Members of the European IVE group**. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. *Euro Surveill*. 2023 May;28(21):2300116.

Camirand-Lemyre F, Merson L, Tirupakuzhi Vijayaraghavan BK, Burrell AJC, Citarella BW, Domingue MP, Lévesque S, Usuf E, Wils EJ, Ohshimo S, Martin-Loeches I, Sandulescu O, Laake JH, Lamontagne F; **ISARIC Clinical Characterisation Group**. Implementation of Recommendations on the Use of Corticosteroids in Severe COVID-19. *JAMA Netw Open*. 2023 Dec 1;6(12):e2346502.

Matuozzo D, Talouarn E, Marchal A, et al. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. *Genome Med*. 2023 Apr 5;15(1):22.

Hocini H, Wiedemann A, Blengio F, Lefebvre C, Cervantes-Gonzalez M, Foucat E, Tisserand P, Surenaud M, Coléon S, Prague M, Guillaumat L, Krief C, Fenwick C, Laouénan C, Bouadma L, Ghosn J, Pantaleo G, Thiébaud R; **French COVID cohort study group**; Lévy Y. Neutrophil Activation and Immune Thrombosis Profiles Persist in Convalescent COVID-19. *J Clin Immunol*. 2023 Mar 21:1-12.

Kartsonaki C, Baillie JK, Barrio NG, Baruch J, et al. Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19. *Int J Epidemiol*. 2023 Feb 28:dyad012.

Lee D, Le Pen J, Yatim A, Dong B, et al. Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children. *Science*. 2023 Feb 10;379(6632):eabo3627.

Rose AM, Nicolay N, Sandonis Martín V et al. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: **I-MOVE-COVID-19 and VEBIS SARI VE networks**, Europe, 2021. *Euro Surveill*. 2023 Nov;28(47):2300186.

Rose AM, Nicolay N, Sandonis Martín V, et al.. Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: **I-MOVE-COVID-19 and VEBIS SARI VE networks**, Europe, 2021 to 2022. *Euro Surveill*. 2023 Nov;28(47):2300187.

HCL (Hospices Civils de Lyon)

2024

Horvat C, Chauvel C, **Casalegno JS**, Benchaib M, Ploin D, Nunes MC; VRS Study Group in Lyon. RSV Severe Infection Risk Stratification in a French 5-Year Birth Cohort Using Machine-learning. *Pediatr Infect Dis J*. 2024 Sep 1;43(9):819-824.

Holmdahl I, Bents SJ, Baker RE, **Casalegno JS**, Trovão NS, Park SW, Metcalf JE, Viboud C, Grenfell B. Differential impact of COVID-19 non-pharmaceutical interventions on the epidemiological dynamics of respiratory syncytial virus subtypes A and B. *Sci Rep*. 2024 Jun 24;14(1):14527.

Caini S, **Casalegno JS**, Rodrigues AP, Lee V, Cohen C, Huang QS, Bruno Caicedo A, Teirlinck A, Guiomar R, Ang LW, Moyes J, Wood T, de Mora D, Bangert M; VRS Study Group in Lyon; Kramer R, Staadegaard L, Heemskerk S, van

Summeren J, Meijer A, Paget J. Change in Age profile of Respiratory Syncytial Virus disease over the course of annual epidemics: a multi-national study. *J Infect.* 2024 May;88(5):106154.

Horvat C, Chauvel C, **Casalegno JS**, Benchaib M, Ploin D, Nunes MC; VRS Study Group in Lyon. RSV Severe Infection Risk Stratification in a French 5-Year Birth Cohort Using Machine-learning. *Pediatr Infect Dis J.* 2024 May 7. doi: 10.1097/INF.0000000000004375. Online ahead of print.

Hites M, Massonnaud CR, Lapique EL, Belhadi D, Jamard S, Goehringer F, Danion F, Reignier J, de Castro N, Garot D, Lacombe K, Tolsma V, Faure E, Malvy D, Staub T, Courjon J, Cazenave-Roblot F, Dyrhol Riise AM, Leturnier P, Martin-Blondel G, Roger C, Akinosoglou K, Moing VL, Piroth L, Sellier P, Lescure X, Trøseid M, Clevenbergh P, Dalgard O, Gallien S, Gousseff M, Loubet P, Vardon-Boune F, Visée C, Belkhir L, Botelho-Nevers É, Cabié A, Kotanidou A, Lanternier F, Rouveix-Nordon E, Silva S, Thiery G, Poignard P, Carcelain G, Diallo A, Mercier N, Terzic V, **Bouscambert-Duchamp M**, **Gaymard A**, Trabaud MA, **Destras G**, **Josset L**, Billard N, Han TH, Guedj J, Couffin-Cadiergues S, Dechanet A, Delmas C, Esperou H, Fougere-Leurent C, Mestre SL, Métois A, Noret M, Bally I, Dergan-Dylon S, Tubiana S, Kalif O, Bergaud N, Leveau B, Eustace J, Greil R, Hajdu E, Halanova M, Paiva JA, Piekarska A, Rodriguez Baño J, Tonby K, Trojánec M, Tsiodras S, Unal S, Burdet C, Costagliola D, Yazdanpanah Y, Peiffer-Smadja N, Mentré F, Ader F; DisCoVeRy study group. Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial. *J Infect.* 2024 Mar;88(3):106120.

Grangier B, Vacheron CH, De Marignan D, **Casalegno JS**, Couray-Targe S, Bestion A, Ader F, Richard JC, Frobert E, Argaud L, Rimmelé T, Lukaszewicz AC, Aubrun F, Dailier F, Fellahi JL, Bohe J, Piriou V, Allaouchiche B, Friggeri A, Wallet F; Lyon Sud COVID-19 ICU. Comparison of mortality and outcomes of four respiratory viruses in the intensive care unit: a multicenter retrospective study. *Sci Rep.* 2024 Mar 20;14(1):6690.

Gaymard A, Picard C, Vazzoler G, Massin P, Frobert E, Sabatier M, Barthelemy M, **Valette M**, Ottmann M, **Casalegno JS**, **Lina B**, **Escuret V**. Impact of the H274Y Substitution on N1, N4, N5, and N8 Neuraminidase Enzymatic Properties and Expression in Reverse Genetic Influenza A Viruses. *Viruses.* 2024 Mar 1;16(3):388.

Staadegaard L, Dückers M, van Summeren J, van Gasteren R, Demont C, Bangert M, Li Y, **Casalegno JS**, Caini S, Paget J. Determining the timing of respiratory syncytial virus (RSV) epidemics: a systematic review, 2016 to 2021; method categorisation and identification of influencing factors. *Euro Surveill.* 2024 Feb;29(5):2300244.

Horvat C, **Casalegno JS**, Masson E, Benveniste C, Haesebaert J, Paget J, Ploin D. Contribution of Infant Rhinovirus Bronchiolitis to Hospital Bed and Ventilation Use. *JAMA Netw Open.* 2024 Feb 5;7(2):e2355033.

Beaulieu M, **Gaymard A**, Massonnaud C, Peiffer-Smadja N, **Bouscambert-Duchamp M**, Carcelain G, et al. Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial. *J Antimicrob Chemother.* 5 sept 2024;dkae301.

Participation à publication – Liste de publiants

Delfraissy JF, Horgan M, Mølbak K, Simón FS, Stadler T, van Dissel J, Van Gucht S, Ricciardi W, Wieler L, Vallance P; **Covid-19 National Scientific Advisory Councils: Presidents or Representatives**. Scientific advisory councils in the COVID-19 response. *Lancet.* 2024 Feb 10;403(10426):510-512.

2023

Richard JC, Frobert E, **Destras G**, Yonis H, Mezidi M, Dhelft F, Trouillet-Assant S, Bastard P, Gervais A, Danjou W, Aubrun F, Roumieu F, Labaune JM, **Josset L**, **Bal A**, **Simon B**, Casanova JL, **Lina B**, Picaud JC, Dupont C, Huissoud C, Bitker

L. Virological and clinical features of acute respiratory failure associated with COVID-19 in pregnancy: a case-control study
Crit Care Resusc. 2023 Oct 18;24(3):242-250.

Lefrançois T, **Lina B**; COVARIS; Autran B. One Health approach at the heart of the French Committee for monitoring and anticipating health risks. *Nat Commun.* 2023 Nov 21;14(1):7540.

Löwensteyn YN, Zheng Z, Rave N, Bannier MAGE, Billard MN, **Casalegno JS**, Pitzer VE, Wildenbeest JG, Weinberger DM, Bont L; Surveillance of Pediatric REspiratory Admissions in Dutch hospitals (SPREAD) Study Group. Year-Round Respiratory Syncytial Virus Transmission in The Netherlands Following the COVID-19 Pandemic: A Prospective Nationwide Observational and Modeling Study. *J Infect Dis.* 2023 Nov 11;228(10):1394-1399.

Khanafer N, Henaff L, Bennia S, Termoz A, Chapurlat R, **Escuret V**, Proriol M, Duvert F, Mena C, Planckaert C, Trehet-Mandez N, Saadatian-Elahi M, Vanhems P. Factors Associated with Long COVID-19 in a French Multicentric Prospective Cohort Study. *Int J Environ Res Public Health.* 2023 Aug 29;20(17):6678. doi: 10.3390/ijerph20176678.

Roy A, Saade C, **Josset L**, Clément B, Morfin F, Destras G, **Valette M**, Icard V, Billaud G, Oblette A, Debombourg M, Garrigou C, Brengel-Pesce K, Generenaz L, Saker K, Hernu R, Pozzetto B, **Lina B**, Trabaud MA, Trouillet-Assant S, Bal A. Determinants of protection against SARS-CoV-2 Omicron BA.1 and Delta infections in fully vaccinated outpatients. *J Med Virol.* 2023 Aug;95(8):e28984

Saadatian-Elahi M, Henaff L, Elias C, Nunes MC, Hot A, Martin-Gaujard G, **Escuret V**, Amour S, Vanhems P. Patient influenza vaccination reduces the risk of hospital-acquired influenza: An incident test negative-case control study in Lyon university hospital, France (2004-2020). *Vaccine.* 2023 Jul 5;41(30):4341-4346. doi: 10.1016/j.vaccine.2023.05.060.

Stuurman AL, Carmona A, Biccler J, Descamps A, Levi M, Baum U, Mira-Iglesias A, Bellino S, Hoang U, de Lusignan S, Bonaiuti R, **Lina B**, Rizzo C, Nohynek H, Díez-Domingo J; DRIVE Study Contributors. Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform. *Front Public Health.* 2023 Jul 20;11:1195409.

Picard G, Fournier L, Maisa A, Grolhier C, Chent S, Huchet-Kervalla C, Sudour J, Pretet M, **Josset L**, Behillil S, Schaeffer J; Laboratory group; COVID-19 Investigation Group; Members of the Laboratory group; Members of the COVID-19 Investigation group. Emergence, spread and characterisation of the SARS-CoV-2 variant B.1.640 circulating in France, October 2021 to February 2022. *Euro Surveill.* 2023 Jun;28(22):2200671.

Escuret V, Terrier O. Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases. *Front Microbiol.* 2023 May 4;14:1137336. doi: 10.3389/fmicb.2023.1137336.

Andrew MK, Pott H, Staadegaard L, Paget J, Chaves SS, Ortiz JR, McCauley J, Bresee J, Nunes MC, Baumeister E, Raboni SM, Giamberardino HIG, McNeil SA, Gomez D, Zhang T, Vanhems P, Koul PA, Coulibaly D, Otieno NA, Dbaiibo G, Almeida MLG, Laguna-Torres VA, Drăgănescu AC, Burtseva E, Sominina A, Danilenko D, Medić S, Díez-Domingo J, **Lina B**. Age Differences in Comorbidities, Presenting Symptoms, and Outcomes of Influenza Illness Requiring Hospitalization: A Worldwide Perspective From the Global Influenza Hospital Surveillance Network. *Open Forum Infect Dis.* 2023 May 7;10(6):ofad244.

Roy Á, Polazzi S, Ploin D, Gillet Y, Javouhey E, **Lina B**; VRS study group in Lyon; Myard-Dury AF, Couray-Targe S, Duclos A, **Casalegno JS**. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs. *Vaccine.* 2023 Jun 7;41(25):3796-3800.

Staadegaard L, Del Riccio M, Wiegersma S, El Guerche-Séblain C, Dueger E, Akçay M, **Casalegno JS**, Dückers M, Caini S, Paget J; NIC Collaborators. The impact of the SARS-CoV-2 pandemic on global influenza surveillance: Insights from 18 National Influenza Centers based on a survey conducted between November 2021 and March 2022. *Influenza Other Respir Viruses.* 2023 May 11;17(5):e13140.

Saade C, Pozzetto B, Yaugel-Novoa M, Oriol G, **Josset L, Lina B**, Paul S, **Bal A**, Trouillet-Assant S. Long-term humoral response following Delta and Omicron BA.1 co-infection. *NPJ Vaccines*. 2023 Apr 20;8(1):57.

Guibert N, Trepot K, Pozzetto B, **Josset L**, Fassier JB, Allatif O, Saker K, Brengel-Pesce K, Walzer T, Vanhems P, Trouillet-Assant S; **Lyon-COVID study group**. A third vaccine dose equalises the levels of effectiveness and immunogenicity of heterologous or homologous COVID-19 vaccine regimens, Lyon, France, December 2021 to March 2022. *Euro Surveill*. 2023 Apr;28(15):2200746.

Teirlinck AC, Johannesen CK, Broberg EK, Penttinen P, Campbell H, Nair H, Reeves RM, Bøås H, Brytting M, Cai W, Carnahan A, **Casalegno JS**, Danis K, De Gascun C, Ellis J, Emborg HD, Gijon M, Guiomar R, Hirve SS, Jiřincová H, Nohynek H, Oliva JA, Osei-Yeboah R, Paget J, Pakarna G, Pebody R, Presser L, Rapp M, Reiche J, Rodrigues AP, Seppälä E, Socan M, Szymanski K, Trebbien R, Večeřová J, van der Werf S, Zambon M, Meijer A, Fischer TK. New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic. *Eur Respir J*. 2023 Apr 3;61(4):2201569.

Barateau V, Peyrot L, Saade C, Pozzetto B, Brengel-Pesce K, Elsensohn MH, Allatif O, Guibert N, Compagnon C, Mariano N, Chaix J, Djebali S, Fassier JB, **Lina B**, Lefsihane K, Espi M, Thauinat O, Marvel J, Rosa-Calatrava M, Pizzorno A, Maucourt-Boulch D, Henaff L, Saadatian-Elahi M, Vanhems P, Paul S, Walzer T, Trouillet-Assant S, Defrance T. Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination. *Sci Transl Med*. 2023 Mar 15;15(687):eade0550.

Casalegno JS, Bents S, Paget J, Gillet Y, Ploin D, Javouhey E, **Lina B**, Morfin F, Grenfell BT, Baker RE; **VRS study group in Lyon**. Application of a forecasting model to mitigate the consequences of unexpected RSV surge: Experience from the post-COVID-19 2021/22 winter season in a major metropolitan centre, Lyon, France. *J Glob Health*. 2023 Feb 3;13:04007.

Colosi E, Bassignana G, Barrat A, **Lina B**, Vanhems P, Bielicki J, Colizza V. Minimising school disruption under high incidence conditions due to the Omicron variant in France, Switzerland, Italy, in January 2022. *Euro Surveill*. 2023 Feb;28(5):2200192.

Quéromès G, Frobert E, **Bouscambert-Duchamp M, Oblette A, Valette M**, Billaud G, **Escuret V, Lina B**, Morfin F, **Gaymard A**. Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: The example of SARS-CoV-2 and monkeypox virus. *J Med Virol*. 2023 Jan;95(1):e28126. doi: 10.1002/jmv.28126.

IPP (Institut Pasteur Paris)

2024

Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, Sève N, McKenna A, Meijer A, Rodrigues AP, Martínez-Baz I, Mlinarić I, Latorre-Margalef N, Túri G, Lazăr M, Mazagatos C, Echeverria A, Abela S, Bourgeois M, Machado A, Dürrwald R, Petrović G, Oroszi B, Jancorienne L, Marin A, Husa P, Duffy R, Dijkstra F, Gallardo García V, Goerlitz L, **Enouf V**, Bennett C, Hooiveld M, Guiomar R, Trobajo-Sanmartín C, Višekruna Vučina V, Samuelsson Hagey T, Lameiras Azevedo AS, Castilla J, Xuereb G, Delaere B, Gómez V, Tolksdorf K, Bacci S, Nicolay N, Kaczmarek M, Rose AM; **European IVE group**. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. *Euro Surveill*. 2024 Feb;29(8):2400089. doi: 10.2807/1560-7917.ES.2024.29.8.2400089.

Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee AK, Johnson K, Morwood K, Rox K, Elgaher WAM, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët JF, **Rameix-Welti MA**, Hirsch AKH, Herold E, Empting M, Lauber C, Schulz TF, Krey T,

- Haid S, Pietschmann T. *Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor*. Nat Commun. 2024 Feb 8;15(1):1173. doi: 10.1038/s41467-024-45241-y.
- Zhang L, Kempf A, Nehlmeier I, Cossmann A, Richter A, Bdeir N, Graichen L, Moldenhauer AS, Dopfer-Jablonka A, Stankov MV, **Simon-Loriere E**, Schulz SR, Jäck HM, Čičin-Šain L, Behrens GMN, Drosten C, Hoffmann M, Pöhlmann S. SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency. Cell. 2024 Feb 1;187(3):596-608.e17. doi: 10.1016/j.cell.2023.12.025.
- Durier C, Ninove L, **van der Werf S**, Lefebvre M, Desaint C, Bauer R, Attia M, Lecompte AS, Lachatre M, Maakaroun-Vermesse Z, Nicolas JF, Verdon R, Kiladjian JJ, Loubet P, Schmidt-Mutter C, Corbin V, Ansart S, Melica G, Resch M, Netzer E, Kherabi Y, Tardieu R, Lelièvre JD, Tartour E, Meyer L, de Lamballerie X, Launay O; ANRS002S CoviCompareP group. Incidence of COVID-19 mRNA vaccine symptomatic breakthrough infections during Omicron circulation in adults with or without infection prior to vaccination. Infect Dis Now. 2024 Aug;54(5):104886. doi: 10.1016/j.idnow.2024.104886. Epub 2024 Mar 16. PMID: 38494117.
- Pouquet M, Decarreaux D, Di Domenico L, Sabbatini CE, Prévot-Monsacre P, Fourié T, Villarroel PMS, Priet S, Blanché H, Sebaoun JM, Deleuze JF, Turbelin C, Rossignol L, Werner A, Kochert F, Grosogeat B, Rabiega P, Laupie J, Abraham N, Noël H, **van der Werf S**, Colizza V, Carrat F, Charrel R, de Lamballerie X, Blanchon T, Falchi A. SARS-CoV-2 infection prevalence and associated factors among primary healthcare workers in France after the third COVID-19 wave. Sci Rep. 2024 Mar 5;14(1):5418. doi: 10.1038/s41598-024-55477-9. PMID: 38443618; PMCID: PMC10914718.
- Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, Meijer A, Kislaya I, Pascu C, Carnahan A, Oroszi B, Ilić M, Maurel M, Melo A, Sandonis Martín V, Trobajo-Sanmartín C, **Enouf V**, McKenna A, Pérez-Gimeno G, Goerlitz L, de Lange M, Rodrigues AP, Lazar M, Latorre-Margalef N, Túri G, Castilla J, Falchi A, Bennett C, Gallardo V, Dürrwald R, Eggink D, Guimar R, Popescu R, Riess M, Horváth JK, Casado I, García MDC, Hooiveld M, Machado A, Bacci S, Kaczmarek M, Kissling E; **European Primary Care Vaccine Effectiveness Group**. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. Euro Surveill. 2024 Mar;29(13):2300403. doi: 10.2807/1560-7917.ES.2024.29.13.2300403.
- Subissi L, Otieno JR, Worp N, Attar Cohen H, Oude Munnink BB, Abu-Raddad LJ, Alm E, Barakat A, Barclay WS, Bhiman JN, Caly L, Chand M, Chen M, Cullinane A, de Oliveira T, Drosten C, Druce J, Effler P, El Masry I, Faye A, Ghedin E, Grant R, Haagmans BL, Hapji C, Herring BL, Hodcroft EB, Ikejezie J, Katawera V, Kassamali ZA, Leo YS, Leung GM, Kondor RJ, Marklewitz M, Mendez-Rico J, Melhem NM, Munster V, Nahapetyan K, Naindoo D, Oh DY, Peacock TP, Peiris M, Peng Z, Poon LLM, Rambaut A, Saha S, Shen Y, Siqueira MM, Volz E, Tessema SK, Thiel V, Triki H, **van der Werf S**, von Eije K, Cunningham J, Koopmans MPG, von Gottberg A, Agrawal A, Van Kerkhove MD. An updated framework for SARS-CoV-2 variants reflects the unpredictability of viral evolution. Nat Med. 2024 May 8. doi: 10.1038/s41591-024-02949-0.
- Gressens SB, **Enouf V**, Créon A, Melica G, Lemonnier F, Dupuis J, El Gnaoui T, Hammoud M, Belhadj⁵, Corinne Haioun K, Le Bouter A, Gallien S, Le Bras F, Fourati S. Serological responses against seasonal influenza viruses in patients with multiple myeloma treated or untreated with daratumumab after two doses of tetravalent vaccine - 2024 Sep:146:107108. doi: 10.1016/j.ijid.2024.107108. Epub 2024 May 23.
- Planchais C, Fernández I, Chalopin B, Bruel T, Rosenbaum P, Beretta M, Dimitrov JD, Conquet L, **Donati F**, Prot M, Porrot F, Planas D, Staropoli I, Guivel-Benhassine F, Baquero E, **van der Werf S**, Haouz A, **Simon-Lorière E**, Montagutelli X, Maillère B, Rey FA, Guardado-Calvo P, Nozach H, Schwartz O, Mouquet H. Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2. iScience. 2024 Jun 22;27(7):110354. doi: 10.1016/j.isci.2024.110354.
- Vieira Antão A, Oltmanns F, Schmidt A, Vihrelehto V, Irrgang P, **Rameix-Welti MA**, Bayer W, Lapuente D, Tenbusch M. Filling two needs with one deed: a combinatory mucosal vaccine against influenza A virus and respiratory syncytial virus. **Front Immunol**. 2024 Jun 21;15:1376395. doi: 10.3389/fimmu.2024.1376395.

Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, **Rameix-Welti MA**, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. *Vaccine*. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067.

Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, **Enouf V**, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. *COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans* - 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258

Euzen V, Xhaard A, Berreira-Ibraim S, Deville L, Quentin A, De Lima Prata PH, Gournay V, Prot M, Rahou Y, Barbet M, Mercier-Delarue S, Peffault De La Tour R, **Simon-Loriere E**, Legoff J. Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant. *Int J Antimicrob Agents*. 2024 Jul 22;64(3):107281. doi: 10.1016/j.ijantimicag.2024.107281.

Marchment, G., Brancotte, B., Schmit, M., **Lemoine, F.**, & Cohen-Boulakia, S. *BioFlow-Insight: facilitating reuse of Nextflow workflows with structure reconstruction and visualization*. *NAR Genomics and Bioinformatics*, 6(3). 2024 Aug 6;6(3):lqae092. doi: 10.1093/nargab/lqae092. eCollection 2024 Sep.

Gascuel, O., & **Lemoine, F.** *Measures of Branch Support in Phylogenetics. Models and Methods for Biological Evolution: Mathematical Models and Algorithms to Study Evolution* (2024): 213.

Morel, M., Zhukova, A., **Lemoine, F.**, & Gascuel, O. *Accurate detection of convergent mutations in large protein alignments with ConDor.* " *Genome Biology and Evolution* 16.4 (2024): evae040.

Cohen-Boulakia, S., & **Lemoine, F.** "Workflows for Bioinformatics Data Integration." *Biological Data Integration: Computer and Statistical Approaches* (2024): 53-85.

Participation à publication – Liste de publiants

Amarsy R, Granger B, Fournier S, Monteil C, Trystram D, Siorat V, Jarlier V, Robert J; Members of the Collégiale de Bactériologie – Virologie – Hygiène. *Novel scores relevant to antimicrobial resistance and hospital-acquired infections developed with data from a multi-hospital consortium in the Parisian region of France*. *J Hosp Infect*. 2024 Jan;143:97-104. doi: 10.1016/j.jhin.2023.09.022.

2023

Chen KY, Karuppusamy J, O'Neill MB, Opuu V, Bahin M, Foulon S, Ibanez P, Quintana-Murci L, Ozawa T, **van der Werf S**, Nghe P, Naffakh N, Griffiths A, Isel C. High-throughput droplet-based analysis of influenza A virus genetic reassortment by single-virus RNA sequencing. *Proc Natl Acad Sci U S A*. 2023 Feb 7;120(6):e2211098120. doi: 10.1073/pnas.2211098120.

Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu AM, Domegan L, Mazagatos C, Dijkstra F, Latorre-Margalef N, Kurečić Filipović S, Machado A, Lazar M, Casado I, Dürrwald R, **van der Werf S**, O'Donnell J, Linares Dopido JA, Meijer A, Riess M, Višekruna Vučina V, Rodrigues AP, Mihai ME, Castilla J, Goerlitz L, Falchi A, Connell J, Castrillejo D, Hooiveld M, Carnahan A, Ilić M, Guiomar R, Ivanciuc A, Maurel M, Omokanye A, Valenciano M; I-MOVE study team. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. *Influenza Other Respir Viruses*. 2023 Jan;17(1):e13069. doi: 10.1111/irv.13069.

Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, Puech J, Saliba M, Sahraoui R, Fémy F, Morel N, Dufloo J, Sanjuán R, Mouquet H, André E, Hocqueloux L, **Simon-Loriere E**, Veyer D, Prazuck T, Péré H, Schwartz O. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. *Nat Commun*. 2023 Feb 14;14(1):824.

Chauvin C, Levillayer L, Roumier M, Nielly H, Roth C, Karnam A, Bonam SR, Bourgarit A, Dubost C, Bousquet A, Le Burel S, Mestiri R, Sene D, Galland J, Vasse M, Groh M, Le Marchand M, Vassord-Dang C, Gautier JF, Pham-Thi N, Verny C, Pitard B, Planchais C, Mouquet H, Paul R, **Simon-Loriere E**, Bayry J, Gilardin L, Sakuntabhai A. Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. *iScience*. 2023 Mar 17;26(3):106124. doi: 10.1016/j.isci.2023.106124.

Djaffardjy, M., Marchment, G., Sebe, C., Blanchet, R., Belhajjame, K., Gaignard, A., **Lemoine, F.**, Cohen-Boulakia, S. Developing and reusing bioinformatics data analysis pipelines using scientific workflow systems. *Computational and Structural Biotechnology Journal*, 21, 2075-2085. 2023 Mar 7;21:2075-2085. doi: 10.1016/j.csbj.2023.03.003. eCollection 2023.

Touret, F., Giraud, E., **Bourret, J., Donati, F.**, Tran-Rajau, J., Chiaravalli, J., **Lemoine, F.**, Agou, F., **Simon-Lorière, E., van der Werf, S.**, de Lamballerie, X. Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages. *Iscience*, 26(4). 2023 Apr 21;26(4):106413. doi: 10.1016/j.isci.2023.106413. Epub 2023 Mar 15.

Bougeard S, Huneau-Salaun A, Attia M, Richard JB, Demeret C, Platon J, Allain V, Le Vu S, Goyard S, Gillon V, Bernard-Stoecklin S, Crescenzo-Chaigne B, Jones G, Rose N, **van der Werf S**, Lantz O, Rose T, Noël H. Application of Machine Learning Prediction of Individual SARS-CoV-2 Vaccination and Infection Status to the French Serosurveillance Survey From March 2020 to 2022: Cross-Sectional Study. *JMIR Public Health Surveill*. 2023 Nov 28;9:e46898. doi: 10.2196/46898.

Temmam S, Montagutelli X, Herate C, **Donati F**, Regnault B, Attia M, Baquero Salazar E, Chretien D, Conquet L, Jouvion G, Pipoli Da Fonseca J, Cokelaer T, Amara F, Relouzat F, Naninck T, Lemaitre J, Derreudre-Bosquet N, Pascal Q, Bonomi M, Bigot T, Munier S, Rey FA, Le Grand R, **van der Werf S**, Eloit M. SARS-CoV-2-related bat virus behavior in human-relevant models sheds light on the origin of COVID-19. *EMBO Rep*. 2023 Apr 5;24(4):e56055. doi: 10.15252/embr.202256055.

Teirlinck AC, Johannesen CK, Broberg EK, Penttinen P, Campbell H, Nair H, Reeves RM, Bøås H, Brytting M, Cai W, Carnahan A, **Casalegno JS**, Danis K, De Gascun C, Ellis J, Emborg HD, Gijon M, Guiomar R, Hirve SS, Jiřincová H, Nohynek H, Oliva JA, Osei-Yeboah R, Paget J, Pakarna G, Pebody R, Presser L, Rapp M, Reiche J, Rodrigues AP, Seppälä E, Socan M, Szymanski K, Trebbien R, Večeřová J, **van der Werf S**, Zambon M, Meijer A, Fischer TK. New perspectives on respiratory syncytial virus surveillance at the national level: lessons from the COVID-19 pandemic. *Eur Respir J*. 2023 Apr 3;61(4):2201569.

Receveur, M., Ottmann, M., Reynes, JM., Eleouet, JF., **Valette, M., Lina, B., Casalegno, JS.** Level of maternal antibodies against respiratory syncytial virus (RSV) nucleoprotein at birth and risk of RSV very severe lower respiratory tract infection. *Influenza Other Respir Viruses*. 2023 Jan;17(1):e13025. doi: 10.1111/irv.13025. Epub 2022 Oct 17.

Briand FX, Souchaud F, Pierre I, Beven V, Hirchaud E, Héroult F, Planel R, Rigau A, Bernard-Stoecklin S, **Van der Werf S, Lina B**, Gerbier G, Etteradossi N, Schmitz A, Niqueux E, Grasland B. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Domestic Cat, France, 2022. *Emerg Infect Dis*. 2023 Aug;29(8):1696-1698. doi: 10.3201/eid2908.230188.

Cokelaer, T., Cohen-Boulakia, S., & **Lemoine, F.** Reprohackathons: promoting reproducibility in bioinformatics through training. *Bioinformatics*, 39(Supplement_1), i11-i20. 2023 Jun 30;39(39 Suppl 1):i11-i20. doi: 10.1093/bioinformatics/btad227.

Picard G, Fournier L, Maisa A, Grolhier C, Chent S, Huchet-Kervalla C, Sudour J, Pretet M, **Josset L, Behillil S**, Schaeffer J; Laboratory group; COVID-19 Investigation Group; Members of the Laboratory group; Members of the COVID-19 Investigation group. Emergence, spread and characterisation of the SARS-CoV-2 variant B.1.640 circulating in France, October 2021 to February 2022. *Euro Surveill.* 2023 Jun;28(22):2200671. doi: 10.2807/1560-7917.ES.2023.28.22.2200671.

Hérate C, Marlin R, Touret F, Dereuddre-Bosquet N, **Donati F**, Relouzat F, Junges L, Galhaut M, **Dehan O**, Sconosciuti Q, Nougairède A, de Lamballerie X, **van der Werf S**, Le Grand R. Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model. *Heliyon*. 2023 Jun;9(6):e16664. doi: 10.1016/j.heliyon.2023.e16664.

de Melo GD, Perraud V, Alvarez F, Vieites-Prado A, Kim S, Kergoat L, Coleon A, Trüeb BS, Tichit M, Piazza A, Thierry A, Hardy D, Wolff N, Munier S, Koszul R, **Simon-Lorière E**, Thiel V, Lecuit M, Lledo PM, Renier N, Larrous F, Bourhy H. Neuroinvasion and anosmia are independent phenomena upon infection with SARS-CoV-2 and its variants. *Nat Commun.* 2023 Jul 26;14(1):4485. doi: 10.1038/s41467-023-40228-7.

Wasniewski M, Boué F, Richomme C, **Simon-Lorière E, Van der Werf S, Donati F, Enouf V**, Blanchard Y, Beven V, Leperchois E, Leterrier B, Corbet S, Le Gouil M, Monchatre-Leroy E, Picard-Meyer E. Investigation on SARS-CoV-2 and other coronaviruses in mink farms in France at the end of the first year of COVID-19 pandemic *PLoS One*. 2023 Aug 25;18(8):e0290444. doi: 10.1371/journal.pone.0290444.

Marc A, Marlin R, **Donati F**, Prague M, Kerioui M, Hérate C, Alexandre M, Dereuddre-Bosquet N, Bertrand J, Contreras V, **Behillil S**, Maisonnasse P, **Van Der Werf S**, Le Grand R, Guedj J. Impact of variants of concern on SARS-CoV-2 viral dynamics in non-human primates. *PLoS Comput Biol.* 2023 Aug 9;19(8):e1010721. doi: 10.1371/journal.pcbi.1010721.

Temmam S, Tu TC, Regnault B, Bonomi M, Chrétien D, Vendramini L, Duong TN, Phong TV, Yen NT, Anh HN, Son TH, Anh PT, Amara F, Bigot T, Munier S, Thong VD, **van der Werf S**, Nam VS, Eloit M. Genotype and Phenotype Characterization of Rhinolophus sp. Sarbecoviruses from Vietnam: Implications for Coronavirus Emergence. *Viruses*. 2023 Sep 8;15(9):1897. doi: 10.3390/v15091897.

Caro, H., Dollin, S., Biton, A., Brancotte, B., Desvillechabrol, D., Dufresne, Y., Li, B., Kornobis, E., **Lemoine, F.**, Maillet, N., Perrin, A., Traut, N., Néron, B., Cokelaer, T. BioConvert: a comprehensive format converter for life sciences. *NAR Genomics and Bioinformatics*, 5(3), lqad074. 2023 Aug 21;5(3):lqad074. doi: 10.1093/nargab/lqad074. eCollection 2023 Sep.

Diot C, Richard CA, Risso-Ballester J, Martin D, Fix J, Eléouët JF, Sizun C, **Rameix-Welti MA**, Galloux M. Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein. *Int J Mol Sci.* 2023 Sep 8;24(18):13862. doi: 10.3390/ijms241813862.

Bourret, J., Borvetö, F., & Bravo, I. G. Subfunctionalisation of paralogous genes and evolution of differential codon usage preferences: The showcase of polypyrimidine tract binding proteins. *Journal of Evolutionary Biology*, 36(10), 1375-1392. 2023 Oct;36(10):1375-1392. doi: 10.1111/jeb.14212. Epub 2023 Sep 5.

Woudenberg T, Pinaud L, Garcia L, Tondeur L, Pelleau S, De Thoisy A, Donnadiou F, Backovic M, Attia M, Hozé N, Duru C, Koffi AD, Castelain S, Ungeheuer MN, Fernandes Pellerin S, Planas D, Bruel T, Coulangeat M, Marlet J, Aidoud A, **Donati F**, Jamard S, **Van Der Werf S**, Debacq C, Leroy V, Lemaignen A, Munier S, Fougère B. Impact of influenza immunity on the mortality among older adults hospitalized with COVID-19: a retrospective cohort study. *Clin Exp Med.* 2023 Oct 31. doi: 10.1007/s10238-023-01203-0.

Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, **Simon-Lorière E**, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients *Med.* 2023 Oct 13;4(10):664-667.

Saunders N, Fernandez I, Planchais C, Michel V, Rajah MM, Baquero Salazar E, Postal J, Porrot F, Guivel-Benhassine F, Blanc C, Chauveau-Le Fric G, Martin A, Grzelak L, Oktavia RM, Meola A, Ahouzi O, Hoover-Watson H, Prot M, Delaune D, Cornelissen M, Deijis M, Meriaux V, Mouquet H, **Simon-Lorière E**, van der Hoek L, Lafaye P, Rey F, Buchrieser J, Schwartz O. TMPRSS2 is a functional receptor for human coronavirus HKU1. *Nature.* 2023 Oct 25. doi: 10.1038/s41586-023-06761-7.

Meslé MMI, Sinnathamby M, Mook P; WHO European Region Respiratory Network Group; Pebody R, Lakhani A, Zambon M, Popovici O, Lazăr M, Ljubović AD, Vukmir NR, Altaş AB, Avci E, Łuniewska K, Szymański K, Gargasienne G, Muralyte S, Dziugyte A, Zahra G, Gonçalves AR, Spedaliero T, Fournier G, Alvarez-Vaca D, Petrović G, Tabain I, Prosenc K, Socan M, Protic J, Dimitrijevic D, Druc A, Apostol M, Kalasnikova KK, Nikisins S, Reiche J, Cai W, Meijer A, Teirlinck A, Larrauri A, Casas I, **Enouf V**, Vaux S, Lomholt FK, Trebbien R, Jirincova H, Sebestova H, Rózsa M, Molnár Z, Aspelund G, Baldvinsdottir GE, Cottrell S, Moore C, Kossyvakis A, Mellou K, Sadikova O, Tamm JK, Bossuyt N, Thomas I, Staroňová E, Kudasheva L, Pleshkov B, Ikonen N, Helve O, Dickson E, Curran T, Komissarova K, Stolyarov K, Vysotskaya V, Shmialiova N, Rakočević B, Vujošević D, Abovyan R, Sargsyan S, Zakhashvili K, Machabishvili A, Koshalko O, Demchyshyna I, Mandelboim M, Glatman-Freedman A, Gunson R, Karanwal S, Guiomar R, Rodrigues AP, Bennett C, Domegan L, Kalaveshi A, Jakupi X, Ovliyakulova G, Korsun N, Vladimirova N. *Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022 2023* - Nov 20;17(11):e13219. doi: 1.1111/irv.13219.

Zaharias, P., **Lemoine, F.**, & Gascuel, O. *Robustness of Felsenstein's Versus Transfer Bootstrap Supports With Respect to Taxon Sampling.* *Systematic Biology*, 72(6), 1280-1295. 2023 Dec 30;72(6):1280-1295. doi: 10.1093/sysbio/syad052.

Communications nationales

Enfissi A. et **Rousset D.**: Surveillance génomique des virus respiratoires et des arbovirus aux Antilles et en Guyane. Séminaire Emergen 2.0, le 06/06/2024.

Regue H., Lefèvre A., Semanas Q., Destras G., Morfin-Sherpa F., **Lina B.**, **Bal A.**, **Simon B.**, **Josset L.**, **Escuret V.** Dynamics of metapneumovirus genotypes revealed by whole-genome sequencing Lyon, France, 2017-2021. Communication orale aux Journées Francophones de Virologie (JFV), Mars 2023, Paris

Zarlenga B., **Gaymard A.**, Wallet F., Richard J-C., Lukaszewicz A-C., **GenEPII Study group.**, Billaud G., Morfin F., Frobert E. Pulmonary herpes simplex virus (HSV) reactivation in COVID-19 patients hospitalized in ICU. RICAI 2023, Paris

Lemoine F. Journées du réseau reproductibilité : « Promoting reproducibility in bioinformatics with Reprohackathons »- Mars 2023

Lemoine F. Kickoff meeting, projet ShaireFAIR: "Importance of workflows in evolutionary bioinformatics" Nov 2023

Lemoine F. Journées du réseau reproductibilité : « Etat des lieux des formations à la reproductibilité en France » Mars 2024

Bourret, J. Communication orale pendant les Journées Nationales d'Infectiologie "Les virus respiratoires : en constante évolution". (30 mn environ). 12 juin 2024

Communications internationales

Parraud D., Grosbois C., Brengel-Pesce K., Mommert M., Guichard A., Fleurie A., Cheynet V., Morfin-Sherpa F., **Gaymard A.**, Trouillet-Assant S. Monitoring of nasal type I IFN response during viral respiratory infections: respiferon study. ESCV, Septembre 2023, Milan

Lemoine F. ISMB2023: "Reprohackathons : Promoting reproducibility in bioinformatics through training" Juil. 2023

Lemoine F. MCEB2024: " The Bayesian phylogenetic bootstrap and its application to short branches and trees" Juin 2024

Fourati S, **Reslan A**, **Casalegno JS**, Marot S, Schnuriger A, Chollet L, Pillet S, Trémeaux P, Dossou NC, Gault E, Salmona M, Mirand A, Imbert BM, Larrat S, Moisan A, Veyrenche N, Engelmann I, Henry A, Handala L, Avettand-Fenoel V, Brichler S, Stephan V, Audureau E, **Rameix-Welti MA**. Characterization of RSV full-length viral genomes after Nirsevimab breakthrough infections in a large national observational real-world study conducted in France 26th Annual Conference of the European Society for Clinical Virology, Frankfurt. September 18-21, 2024.

Conférences invitées

Lina B, COVID-19, bilan et perspective – produire des connaissances scientifiques en temps de crise, ANR & ANRS-MIE, Paris 2 février 2023

Lina B, One health, QCMD international advisory meeting, Glasgow, 22 février 2023

Lina B, COVID-19 – an IV, webinaire SMHP, 17 mars 2023

Lina B, Why PCR should be preferentially used given the low sensitivity of antigen tests, 33rd ECCMID, Copenhagen, avril 2023

Lina B, Adult vaccination strategies : advances in prevention and its challenges, Fundation Bamberg, Berlin, juin 2023

Lina B, Biodiversité des génomes viraux, avec un focus sur le SARS-CoV-2 : détection et analyse de la variabilité des génomes viraux dans l'environnement. Colloque de l'académie d'agriculture sur l'ADN et l'ARN environnemental, Paris septembre 2023

Lina B, les virus influenza, colloque des académies de médecine et vétérinaires, Maison Alfort octobre 2023

Lina B, Comment investiguer un virus émergent ? Journées de formation en microbiologie, Lausanne, novembre 2023

Lina B, Surveillance moléculaire des virus des infections respiratoires. Formation SpF sur le typage moléculaire pour la surveillance et le contrôle des maladies infectieuses, Saint Maurice, décembre 2023

Lina B, Co-infections à virus respiratoires, 43e RICAI, Paris décembre 2023

Escuret V. Un vaccin trivalent ou quadrivalent ? Communication orale au Congrès digital Prescriptions et parcours de soins chez le sujet âgé (PAPA), 7ème édition, 13 Juin 2024

Rameix-Welti MA, Integrative Structural Biology Meeting, Marseille. Respiratory Syncytial Viral Factories are druggable biocondensates, 2023

Rameix-Welti MA, Journée scientifique de l'alliance nationale pour les sciences du vivant et de la santé – Paris. Liquid viral factories: the example of respiratory syncytial virus, 2023

Rameix-Welti MA, PANTHER Technical Flu Meeting Institut Pasteur, Paris, France. « Influenza viruses: intra host dynamics », 2023

Rameix-Welti MA, Séminaire AC vaccin virotes respiratoires de l'ANRS MIE Thury-Sous-Clermont, Oise. Animation d'un atelier sur le sujet VRS et évolution virale, 2024 (janv)

Rameix-Welti MA, RSV surveillance meeting, reseau PROMISE, Bilthoven, The Netherlands. Surveillance du VRS dans le cadre de l'introduction du nirsevimab en France, 2024 (fev)

Rameix-Welti MA, Les journées I-reivac. Stratégies préventives VRS Mécanismes action et échappement 2024 (mars)

Van der Werf S, Treatment or prevention? Global and public health perspectives of guideline development. Symposium ESGREV & ISIRV – Tackling influenza and RSV management in the post-COVID era, 33rd ECCMID. Avril 2023.

Van der Werf S, Laboratory-based and Point of Care diagnosis ESWI Symposium - Seasonal influenza, COVID-19 and RSV: where do we go?, 34th ECCMID, Barcelona, Spain, April 2024

Van der Werf S, ESCMID-appointed chair. COVID-19: are we meeting the challenge? Pfizer-ECCMID Satellite Symposium, 34th ECCMID, Barcelona, Spain, April 2024.